<DOC>
	<DOCNO>NCT00818805</DOCNO>
	<brief_summary>To evaluate efficacy olopatadine 0.1 % use OHIO Chamber patient seasonal allergic conjunctivitis .</brief_summary>
	<brief_title>Efficacy Investigation Study Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber Patients With Seasonal Allergic Rhinitis ( SAR )</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Tranilast</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Age/Gender : male female age &gt; 20 &lt; 65 year ( time obtain consent ) . 2 . Positive case blood specific IgE antibody quantification cedar pollen show class 26 health checkup conduct within past 3 year . 3 . Cases diagnose patient seasonal allergic conjunctivitis judge eligible subject say study investigator coinvestigator result medical examination conduct day study prior . 4 . Cases give consent study participation free writing , understand content say study . 1 . Cases ocular disease require treatment allergic conjunctivitis . 2 . Cases inflammatory ocular disease external/anterior part eye may affect drug efficacy evaluation . 3 . Cases respiratory disease bronchial asthma allergic rhinitis . 4 . Cases past history anaphylaxis . 5 . Cases past history hypersensitivity olopatadine hydrochloride/tranilast . 6 . Cases undergo immunotherapy ( hyposensitization therapy ; modulate therapy ) . 7 . Patients pregnant , lactating woman , may pregnant , case wish pregnant study period . 8 . Other case judge ineligible participation main study doctor charge study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>conjunctivitis</keyword>
</DOC>